NCT03558919View on ClinicalTrials.gov

Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder

PHASE4CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

December 30, 2017

Study Completion Date

December 30, 2017

Conditions
Overactive Bladder
Interventions
DRUG

Mirabegron 25mg

DRUG

Solifenacin Succinate 5 MG

Trial Locations (1)

1100

Bangabandhu Sheikh Mujib Medical University, Dhaka

All Listed Sponsors
lead

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

OTHER

NCT03558919 - Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder | Biotech Hunter | Biotech Hunter